Antiarrhythmic drug therapy for sustained ventricular arrhythmias complicating acute myocardial infarction

Critical Care Medicine

Volumn 39, Issue 1, 2011, Pages 78-83

  Piccini, Jonathan P ^a   Schulte, Phillip J ^a   Pieper, Karen S ^a   Mehta, Rajendra H ^a   White, Harvey D ^c   Van De Werf, Frans ^d   Ardissino, Diego ^e   Califf, Robert M ^b   Granger, Christopher B ^a   Ohman, E Magnus ^a   Alexander, John H ^a  

^a DUKE UNIVERSITY MEDICAL CENTER   (United States)

^b DUKE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c AUCKLAND CITY HOSPITAL   (New Zealand)

^d UNIVERSITY HOSPITALS LEUVEN   (Belgium)

^e Parma Hospital   (Italy)

Author keywords

acute coronary syndrome; antiarrhythmic drug therapy; clinical trials; ventricular arrhythmia; ventricular fibrillation; ventricular tachycardia

Indexed keywords

AMIODARONE; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; LIDOCAINE;

ACUTE HEART INFARCTION; ADULT; AGED; ARTICLE; CONTROLLED STUDY; FEMALE; FOLLOW UP; HEART VENTRICLE FIBRILLATION; HEART VENTRICLE TACHYCARDIA; HUMAN; MAJOR CLINICAL STUDY; MALE; MORTALITY; PRIORITY JOURNAL; RETROSPECTIVE STUDY; RISK; ST SEGMENT ELEVATION MYOCARDIAL INFARCTION; SURVIVAL;

EID: 78651250704     PISSN: 00903493     EISSN: 15300293     Source Type: Journal    
DOI: 10.1097/CCM.0b013e3181fd6ad7     Document Type: Article

References (22)

1. Newby KH, Thompson T, Stebbins A, et al: Sustained ventricular arrhythmias in patients receiving thrombolytic therapy: Incidence and outcomes. The GUSTO Investigators. Circulation 1998;98:2567-2573
2. Piccini JP, Berger JS, Brown DL: Early sustained ventricular arrhythmias complicating acute myocardial infarction. Am J Med 2008;121:797-804
3. Sadowski ZP, Alexander JH, Skrabucha B, et al: Multicenter randomized trial and a systematic overview of lidocaine in acute myocardial infarction. Am Heart J 1999;137: 792-798
4. Dorian P, Cass D, Schwartz B, et al: Amiodarone as compared with lidocaine for shockresistant ventricular fibrillation. N Engl J Med 2002;346:884-890 (Pubitemid 34984636)
5. European Heart Rhythm Association, Heart Rhythm Society, Zipes DP, et al: ACC/AHA/ESC 2006 guidelines for management of patients with ventricular arrhythmias and the prevention of sudden cardiac death: A report of the American College of Cardiology/American Heart Association Task Force and the European Society of Cardiology Committee for Practice Guidelines (Writing Committee to Develop Guidelines for Management of Patients With Ventricular Arrhythmias and the Prevention of Sudden Cardiac Death). J Am Coll Cardiol 2006;48:e247-e346
6. The Global Use of Strategies to Open Occluded Coronary Arteries (GUSTO) IIb Investigators: A comparison of recombinant hirudin with heparin for the treatment of acute coronary syndromes. N Engl J Med 1996;335:775-782
7. The Global Use of Strategies to Open Occluded Coronary Arteries (GUSTO III) Investigators: A comparison of reteplase with alteplase for acute myocardial infarction. N Engl J Med 1997;337:1118-1123
8. Al-Khatib SM, Stebbins AL, Califf RM, et al: Sustained ventricular arrhythmias and mortality among patients with acute myocardial infarction: Results from the GUSTO-III trial. Am Heart J 2003;145:515-521
9. Lee KL, Woodlief LH, Topol EJ, et al: Predictors of 30-day mortality in the era of reperfusion for acute myocardial infarction. Results from an international trial of 41,021 patients. GUSTO-I Investigators. Circulation 1995;91:1659-1668
10. Rosenbaum P, Rubin D: Reducing bias in observational studies using subclassification on the propensity score. J Am Stat Assoc 1984;79:516-524
11. Rosenbaum P, Rubin D: The central role of the propensity score in observational studies for causal effects. Biometrika 1983;70:41-55
12. Lunceford JK, Davidian M: Stratification and weighting via the propensity score in estimation of causal treatment effects: A comparative study. Stat Med 2004;23:2937-2960
13. Mehta RH, Starr AZ, Lopes RD, et al: Incidence of and outcomes associated with ventricular tachycardia or fibrillation in patients undergoing primary percutaneous coronary intervention. JAMA 2009;301:1779-1789
14. Piccini JP, Hranitzky PM, Kilaru R, et al: Relation of mortality to failure to prescribe beta blockers acutely in patients with sustained ventricular tachycardia and ventricular fibrillation following acute myocardial infarction (from the VALsartan In Acute myocardial iNfarcTion trial [VALIANT] Registry). Am J Cardiol 2008;102:1427-1432
15. Hine LK, Laird N, Hewitt P, et al: Metaanalytic evidence against prophylactic use of lidocaine in acute myocardial infarction. Arch Intern Med 1989;149:2694-2698
16. Antman EM, Anbe DT, Armstrong PW, et al: ACC/AHA guidelines for the management of patients with ST-elevation myocardial infarction- executive summary: A report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to Revise the 1999 Guidelines for the Management of Patients With Acute Myocardial Infarction). Circulation 2004;110:588-636
17. Piccini JP, Berger JS, O'Connor CM: Amiodarone for the prevention of sudden cardiac death: A meta-analysis of randomized controlled trials. Eur Heart J 2009;30: 1245-1253
18. Waldo AL, Camm AJ, deRuyter H, et al: Effect of d-sotalol on mortality in patients with left ventricular dysfunction after recent and remote myocardial infarction. The SWORD Investigators. Survival With Oral d-Sotalol. Lancet 1996;348:7-12
19. Camm AJ, Pratt CM, Schwartz PJ, et al: Mortality in patients after a recent myocardial infarction: A randomized, placebo-controlled trial of azimilide using heart rate variability for risk stratification. Circulation 2004;109: 990-996
20. The Cardiac Arrhythmia Suppression Trial (CAST) Investigators: Preliminary report: Effect of encainide and flecainide on mortality in a randomized trial of arrhythmia suppression after myocardial infarction. N Engl J Med 1989;321:406-412
21. Boutitie F, Boissel JP, Connolly SJ, et al: Amiodarone interaction with beta-blockers: Analysis of the merged EMIAT (European Myocardial Infarct Amiodarone Trial) and CAMIAT (Canadian Amiodarone Myocardial Infarction Trial) databases. The EMIAT and CAMIAT Investigators. Circulation 1999;99: 2268-2275
22. Thomas KL, Al-Khatib SM, Lokhnygina Y, et al: Amiodarone use after acute myocardial infarction complicated by heart failure and/or left ventricular dysfunction may be associated with excess mortality. Am Heart J 2008;155:87-93